Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04495179 · ClinicalTrials.gov registry record · Phase 2
A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT04495179 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 30 participants.
The verdict
NCT04495179, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase II, international, open-label, two-arm, non-randomised study of AZD4635 in participants with metastatic castration-resistant prostate cancer (mCRPC).
Interventions
- DRUG Durvalumab
- DRUG Cabazitaxel
- DRUG AZD4635
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2022-08-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04495179
The ClinicalTrials.gov registry entry for NCT04495179 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Durvalumab is the first listed.
NCT04495179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04495179 about?
NCT04495179 is a clinical study titled "A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.". This is a Phase II, international, open-label, two-arm, non-randomised study of AZD4635 in participants with metastatic castration-resistant prostate cancer (mCRPC).
What is the current status of trial NCT04495179?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-08-04. Estimated completion is 2022-08-08.
What interventions are being tested in trial NCT04495179?
The interventions under investigation include: Durvalumab (DRUG), Cabazitaxel (DRUG), AZD4635 (DRUG).
Who is sponsoring clinical trial NCT04495179?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.